What is CUSIP 60770K107?

CUSIP 60770K107 is the security identifier used in SEC filing datasets for MRNA - Moderna, Inc. - Common Stock.

Who owns MRNA - Moderna, Inc. - Common Stock based on 13F filings?

717 institutions reported positions in MRNA - Moderna, Inc. - Common Stock as of Q1 2026. Open the latest holders period and ownership history tables on this page for position-level details.

Security Snapshot

Moderna, Inc. - Common Stock (MRNA) Institutional Ownership

CUSIP: 60770K107

13F Institutional Holders and Ownership History from Q4 2018 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

717

Shares (Excl. Options)

308,159,594

Price

$50.80

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period

Security type / class: Equity / Common Stock
Symbol: MRNA on Nasdaq
All holders as of 31 Mar 2026: Q1 2026
Total 13F shares: 308,159,594
Total 13F value: $15,635,282,803
Portfolio coverage rank: 0.01%
Share change: +3,813,347
Value change: +$512,851,507
Number of holders: 717
Shares outstanding: 397,148,913
SEC-reported price per share: $52.88
Insider filing price: $52.88

13F Shares, Excluding Options vs Price

13F Value, Excluding Options

Total Investors

Key facts

MRNA - Moderna, Inc. - Common Stock is tracked under CUSIP 60770K107.
717 institutions reported positions in Q1 2026.
3 significant owners is listed from Schedule 13D/13G reporting.

Change

Holder count moved from 664 to 717 between Q4 2025 and Q1 2026.
SEC-reported value moved from $8,970,189,509 to $15,635,282,803.

Research use

You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 717 institutions filings for Q1 2026.

Open SEC evidence

Security key

60770K107

Latest holder period

Q1 2026

13F holders

717

13D/G owners

CIK / CUSIP context first

Open Q1 2026 holders MRNA full holder history Moderna, Inc. SEC filings Moderna, Inc. company facts Moderna, Inc. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

Recent Quarterly Holder Reports

Open recent reporting periods for CUSIP 60770K107:

Q1 2026 (717 holders) Q4 2025 (664 holders) Q3 2025 (634 holders) Q2 2025 (663 holders) Q1 2025 (678 holders) Q4 2024 (729 holders) Q3 2024 (765 holders) Q2 2024 (939 holders) Q1 2024 (887 holders) Q4 2023 (869 holders)

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows

Security

MRNA

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
FMR LLC	11%	+49%	$1,217,980,317	+$393,401,259	41,301,469	+48%	FMR LLC	30 Jan 2026
VANGUARD CAPITAL MANAGEMENT LLC	6.5%		$1,317,438,259		25,933,824		Vanguard Capital Management	31 Mar 2026
BAILLIE GIFFORD & CO	5.3%	-17%	$814,988,354	-$172,974,542	20,580,514	-18%	BAILLIE GIFFORD & CO	31 Dec 2025

As of 31 Mar 2026, 717 institutional investors reported holding 308,159,594 shares of Moderna, Inc. - Common Stock (MRNA). This represents 78% of the company’s total 397,148,913 outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share

64%

Institution	Ownership %	Shares Held	Share Change %	Portfolio %	Holdings Value
FMR LLC	11%	45,672,024	+63%	0.12%	$2,320,138,832
BlackRock, Inc.	7.5%	29,635,876	-8.8%	0.03%	$1,505,502,493
VANGUARD CAPITAL MANAGEMENT LLC	5.8%	22,872,458	0%	0.03%	$1,161,920,866
BAILLIE GIFFORD & CO	5%	19,985,876	-2.9%	1%	$1,015,282,501
Capital World Investors	4.7%	18,697,694	+46%	0.13%	$949,814,890
VANGUARD PORTFOLIO MANAGEMENT LLC	3.9%	15,616,367	0%	0.04%	$793,311,444
STATE STREET CORP	3.7%	14,861,409	-9.2%	0.03%	$754,959,577
GEODE CAPITAL MANAGEMENT, LLC	2.4%	9,435,132	+2.3%	0.03%	$478,491,677
TWO SIGMA INVESTMENTS, LP	2.3%	9,086,404	+24%	0.38%	$461,589,323
MORGAN STANLEY	2.1%	8,471,263	-4.5%	0.03%	$430,340,232
Theleme Partners LLP	2%	8,048,245	-0.42%	27%	$408,850,846
GOLDMAN SACHS GROUP INC	1.7%	6,603,697	+67%	0.04%	$335,467,804
Invesco Ltd.	1.2%	4,784,758	-32%	0.04%	$243,065,715
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	1.2%	4,734,356	+2.4%	0.04%	$240,505,285
Flagship Pioneering, LLC	1.2%	4,632,149	0%	20%	$235,313,169
UBS Group AG	1.1%	4,407,907	+7.9%	0.04%	$223,921,675
BNP PARIBAS FINANCIAL MARKETS	1.1%	4,317,219	0%	0.14%	$219,314,725
Alyeska Investment Group, L.P.	1%	4,051,185	+25%	0.58%	$205,800,198
NORTHERN TRUST CORP	0.74%	2,952,041	-1.7%	0.02%	$149,963,683
BANQUE PICTET & CIE SA	0.69%	2,748,754	-12%	1.6%	$139,636,703
FIRST TRUST ADVISORS LP	0.6%	2,392,693	+59%	0.09%	$121,548,795
WELLINGTON MANAGEMENT GROUP LLP	0.59%	2,357,597	+2730%	0.02%	$119,765,927
Merck & Co., Inc.	0.58%	2,308,190	0%	34%	$117,256,052
DIMENSIONAL FUND ADVISORS LP	0.54%	2,132,167	+19%	0.02%	$108,227,937
FEDERATED HERMES, INC.	0.5%	1,977,079	-9.2%	0.16%	$100,435,613

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods

Latest

Q1 2026

Rows shown

1-25 of 30

Period	13F Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2026 Q1	308,159,594	$15,635,282,803	+$512,851,507	$1,552,767,231	$1,529,510,069	$50.80	717
2025 Q4	304,073,383	$8,970,189,509	+$762,808,902	$1,286,279,687	$1,214,563,127	$29.49	664
2025 Q3	275,125,683	$7,105,644,631	-$450,789,607	$1,128,519,908	$1,035,847,251	$25.83	634
2025 Q2	291,423,621	$8,041,462,409	+$359,301,164	$953,917,304	$778,127,109	$27.59	663
2025 Q1	278,813,548	$7,903,142,271	-$59,165,632	$879,746,945	$673,661,963	$28.35	678
2024 Q4	276,578,373	$11,499,056,660	+$341,051,932	$1,001,589,736	$786,508,119	$41.58	729
2024 Q3	260,519,054	$17,396,828,362	-$359,670,897	$1,243,213,357	$701,421,710	$66.83	765
2024 Q2	261,395,055	$31,036,767,708	-$43,788,037	$1,431,835,450	$1,094,475,375	$118.75	939
2024 Q1	262,225,074	$27,942,962,472	+$671,576,108	$993,221,671	$1,286,942,056	$106.56	887
2023 Q4	256,350,763	$25,504,353,761	+$907,888,206	$1,079,174,407	$1,499,592,291	$99.45	869
2023 Q3	246,373,071	$25,443,040,671	-$303,969,124	$1,068,658,896	$1,316,134,609	$103.29	872
2023 Q2	246,506,415	$29,955,571,272	-$272,422,709	$1,008,405,288	$874,358,642	$121.50	942
2023 Q1	249,344,037	$38,273,515,844	+$239,644,701	$1,358,217,438	$1,574,550,446	$153.58	996
2022 Q4	248,479,248	$44,642,318,628	+$419,105,140	$2,336,618,593	$2,478,808,951	$179.62	1,049
2022 Q3	246,689,392	$29,178,218,716	+$223,399,465	$1,254,027,475	$1,052,298,869	$118.25	882
2022 Q2	244,256,119	$34,891,994,437	-$466,757,538	$1,485,721,310	$1,271,813,410	$142.85	957
2022 Q1	248,043,088	$42,733,575,812	+$209,409,354	$2,950,839,880	$2,493,864,042	$172.26	983
2021 Q4	246,080,857	$62,455,582,704	-$6,658,229	$6,423,558,004	$4,434,992,654	$253.98	1,078
2021 Q3	225,302,088	$86,681,348,769	+$6,751,024,992	$8,721,579,062	$7,515,706,532	$384.86	1,120
2021 Q2	207,880,167	$48,837,794,090	+$5,169,371,723	$4,129,479,856	$3,516,026,784	$234.98	873
2021 Q1	188,072,205	$24,617,994,062	+$2,907,518,589	$2,100,566,245	$1,820,607,735	$130.95	752
2020 Q4	168,732,531	$17,626,423,609	-$527,763,419	$1,688,796,948	$1,263,437,595	$104.47	688
2020 Q3	204,933,447	$14,493,668,331	-$999,957,835	$707,320,000	$543,636,000	$70.75	535
2020 Q2	219,125,612	$14,064,229,526	+$1,607,162,122	$355,581,000	$412,038,000	$64.21	477
2020 Q1	195,768,954	$5,863,724,828	+$637,559,905	$54,867,000	$94,208,000	$29.95	285